Research programme: Duchenne muscular dystrophy therapeutics - Genethon

Drug Profile

Research programme: Duchenne muscular dystrophy therapeutics - Genethon

Alternative Names: micro-dystrophin program - Genethon

Latest Information Update: 01 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genethon
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Duchenne muscular dystrophy

Most Recent Events

  • 27 Jul 2017 Pharmacodynamics data from a preclinical trial in Duchenne muscular dystrophy released by Sarepta Therapeutics
  • 21 Jun 2017 Genethon and Sarepta Therapeutics enter an option agreement for Duchenne muscular dystrophy therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top